2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Tumour treating fields (TTFields) added to first-line chemotherapy (gemcitabine and nab-paclitaxel [GnP]) extends survival in individuals with locally advanced pancreatic adenocarcinoma (LA-PAC) in the PANOVA-3 study.

The combination of niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) results in significant improvements in radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with alterations in homologous recombination repair (HRR) genes, as shown by the results of the phase III AMPLITUDE trial.

In the primary analysis of the ASCENT-04/KEYNOTE-D19 study, a combination regimen comprising sacituzumab govitecan (SG) and pembrolizumab delivers significant progression-free survival (PFS) benefit in women with previously untreated PD-L1+ advanced triple-negative breast cancer (TNBC).

In patients undergoing abdominal-pelvic radiation therapy (RT), treatment with olanzapine along with an antiemetic medication leads to a substantial decrease in RT-induced nausea and vomiting (RINV), with no serious adverse effects, reports a study presented at ASCO 2025.

Darolutamide demonstrated clinically meaningful delays in pain progression and deterioration of important patient-relevant health-related quality of life (HRQoL) outcomes vs placebo in men with metastatic hormone-sensitive prostate cancer (mHSPC), according to phase III ARANOTE trial findings presented at ASCO 2025. [ASCO 2025, abstract 5004]